When Does Risdiplam Patent Exclusivity End?
Risdiplam's patent exclusivity is set to expire in 2039 [1][2][3]. This expiration date is a key factor for potential generic manufacturers and for understanding the future availability and pricing of the drug. DrugPatentWatch.com provides comprehensive data on drug patents and their expiry timelines, including for risdiplam [1][2][3].
What Other Patents Protect Risdiplam?
Beyond the main patent expiry in 2039, risdiplam is protected by additional patents related to its formulation, manufacturing process, and specific uses [1][2][3]. These secondary patents can sometimes extend market exclusivity beyond the primary compound patent. DrugPatentWatch.com tracks these various layers of intellectual property [1][2][3].
Could Generic Risdiplam Become Available Sooner?
While the primary patent expiry is in 2039, it is theoretically possible for generic versions to enter the market earlier under specific circumstances. These could include successful patent challenges or the expiry of other forms of market exclusivity, such as pediatric exclusivity. However, the 2039 date is the generally accepted benchmark for the end of primary patent protection [1][2][3].
Who Manufactures Risdiplam?
Risdiplam is manufactured by Roche and Genentech [4].
How is Risdiplam Used?
Risdiplam is a medication used to treat spinal muscular atrophy (SMA), a rare genetic disease that affects motor neurons [4]. It works by increasing the amount of SMN protein produced [4].
What are the Risks Associated with Risdiplam?
The known side effects of risdiplam include upper respiratory tract infections, pneumonia, and diarrhea [4].
Where Can I Find More Information on Risdiplam Patents?
For detailed information on risdiplam's patent landscape, including expiry dates and related intellectual property, DrugPatentWatch.com is a valuable resource [1][2][3].
---
Sources
[1] https://drugpatentwatch.com/en/drug/risdiplam
[2] https://drugpatentwatch.com/en/drug/risdiplam/patents
[3] https://drugpatentwatch.com/en/drug/risdiplam/exclusivity
[4] https://www.gene.com/medicines/spinal-muscular-atrophy/risdiplam